Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014.

Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at March 31, 2014."The second half of 2014 will be an exciting time for Nektar as we look forward to significant milestones for a number of our late-stage clinical programs," said Howard W. Robin, President and Chief Executive Officer of Nektar. "The first of these is the potential US and EU approvals of Movantik™ with our partner AstraZeneca. If approved, Movantik would be the first oral targeted therapy approved for opioid induced constipation, a debilitating condition that occurs in up to 80%* of the 69 million chronic pain patients worldwide. Our partner Baxter has completed dosing in their Phase 3 study for BAX 855, a longer-acting PEGylated Factor VIII therapy to treat hemophilia A and plans to file the BLA in the U.S. by the end of this year. In our proprietary pipeline, we are on track for topline results from the Phase 3 breast cancer study for NKTR-102 in Q1 2015."

Revenue in the second quarter of 2014 was $28.5 million as compared to $33.9 million in the second quarter of 2013. Year-to-date revenue for 2014 was $48.3 million as compared to $56.9 million in the first half of 2013.  The decrease in revenue in the second quarter and first half of 2014 as compared to the same periods in 2013 is primarily due to decreased manufacturing activity.  Revenue included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.8 million and $10.6 million in the second quarter and first half of 2014, respectively, and $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively. This non-cash royalty revenue is offset by non-cash interest exp
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... quantum dot market report analyzes the ecosystem of the quantum ... includes medical devices, display, and others. The others segment consists ... QD laser, and transistor. The application segment covers the market ... report also provides the geographic view for major regions like ... , Asia-Pacific (APAC), and Rest ...
(Date:9/2/2015)... Colo. , Sept. 2, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in Boston.  The public is welcome ... on the Array BioPharma website.Event: Wells Fargo Securities ... Thursday, September 10, 2015Time:  , 10:20 a.m. Eastern ...
(Date:9/2/2015)... STAAR Surgical Company (NASDAQ: STAA ), a ... systems for the eye, today announced that its Board of ... Company,s Board. Mr. Wall was formerly the ... -based investment firm, for more than nine years. Mr. Wall ... chair of the Corporate Governance Committee and member of the ...
Breaking Medicine Technology:Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2William P. Wall Appointed to STAAR Surgical Board of Directors 2
... 17, 2012  Tengion, Inc. (NASDAQ: TNGN ), ... recently completed a successful Pre-IND meeting with the U.S. ... program, the Neo-Kidney Augment™. The FDA and the Company ... study program required to support an Investigational New Drug ...
... Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" ... Distribution Specialists, LLC ("HDS") are pleased to announce that ... and Hemostasis Summit of North America (the "THSNA") to ... Chicago.  "Participation as an official exhibitor ...
Cached Medicine Technology:Tengion Announces IND Filing for Neo-Kidney Augment Expected During First Half of 2013 2Tengion Announces IND Filing for Neo-Kidney Augment Expected During First Half of 2013 3Tengion Announces IND Filing for Neo-Kidney Augment Expected During First Half of 2013 4Tengion Announces IND Filing for Neo-Kidney Augment Expected During First Half of 2013 5Sunpeaks Ventures to Exhibit Clotamin at the first-ever Thrombosis and Hemostasis Summit of North America 2
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the world ... be spotlighting its award-winning print and artwork inspection solutions, ScanProof and ArtProof ... 17 at the Olympia London, booth #F33 , Be the first to get a ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... data collection, cloud analytics and workflow solutions today announced the complete faculty ... September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry experts ...
(Date:9/3/2015)... ... September 03, 2015 , ... “Love in Tokyo” an ... Google Play , and Amazon and will be released on DVD early ... Darling is a Foreigner,” Itsuka, an actress and singer/songwriter, and Jason London, lead from ...
(Date:9/3/2015)... ... ... types of people who have a hard time gaining weight , it seems that ... those that have a fast metabolism. In order to help those people who have a ... slowing down metabolism. , The first thing to do is to space out meals. When ...
(Date:9/3/2015)... ... September 03, 2015 , ... Doctor Kayode Sotonwa can be counted on ... His perspective on internal medicine keeps patients happy and healthy, something that is important ... of the season, but even more so in the fall, when holiday eating and ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2
... Access to Basic,Care plan could help thousands of ... of Community and Economic Development,Secretary Dennis Yablonsky said ... "The vast majority of Pennsylvania,s uninsured adults ... businesses that struggle to make a,profit," said Yablonsky. ...
... D,ALENE, Idaho, May 23 NightHawk,Radiology Holdings, Inc. ... radiology,solutions to radiology groups and hospitals throughout the ... the Goldman Sachs 29th Annual,Global Healthcare Conference in ... at,8:40 am PDT. Presenting at the conference will ...
... also lower cholesterol, study says , , FRIDAY, May ... in antioxidants and may help protect against liver damage, ... The berries of the plant -- indigenous to the ... well known for their high levels of antioxidants and ...
... Linkwell,Corporation (Linkwell) (OTC Bulletin Board: LWLL), a ... disinfectants in China,announced today that it was ... relief efforts. The Chinese government, non-government,organizations (NGOs) ... scale in response to the earthquake in ...
... John G. Rangos Sr. Research Center at Childrens Hospital ... for the development of new therapies to treat hypertriglyceridemia, ... obese and diabetic. Results of their study are published ... Investigation. , Scientists in the Division of Immunogenetics at ...
... make a world of difference for Singer Songwriter Katie ... Reider Beginning May 23, ... songwriter Katie Reider, age 29, has inspired the hearts of,thousands with ... across the country are banding together to help Katie,during her ongoing ...
Cached Medicine News:Health News:PA ABC Will Benefit Commonwealth's Small Businesses, DCED Secretary Says 2Health News:NightHawk Radiology Holdings, Inc. to Speak at the Goldman Sachs 29th Annual Global Healthcare Conference 2Health News:Linkwell Corporation Runs 24/7 Disinfectant Operations to Support China's Earthquake Relief Efforts 2Health News:Linkwell Corporation Runs 24/7 Disinfectant Operations to Support China's Earthquake Relief Efforts 3Health News:Pittsburgh scientists find protein may be key to new therapies for elevated triglycerides 2Health News:Katie Reider - Listen to Her Songs, Hear Her Story, Log Onto www.500kin365.org 2Health News:Katie Reider - Listen to Her Songs, Hear Her Story, Log Onto www.500kin365.org 3
... tray is specifically designed for a variety ... x 13.34cm dot blot transfer membranes. The ... a standard microplate for compatibility with various ... available dot blot membranes without trimming., With ...
Mini Trans-Blot and PowerPac 300 System, 110-120 V...
... The GENIE is the proven electrophoretic transfer apparatus ... field uniformity. Its design allows for a very ... with a low voltage power source such as ... volts/cm. The result is exceptionally rapid and exact ...
... transfer apparatus incorporating state-of-the-art plate electrodes for the ... a very close positioning of the electrodes which, ... such as a battery charger, creates a high ... and exact electrophoretic transfer. ...
Medicine Products: